John E Murphy

Interests

Research

Application of pharmacokinetics to patient care; medication safety; drug-drug interactions

Teaching

Flipped classroom, online learning, use of technology in learning

Courses

Scholarly Contributions

Journals/Publications

• Murphy, J., & Murphy, J. E. (0). The writing on the wall: an allegory of fish management. Pharmacotherapy, 16(4).
• Murphy, J., Hines, L. E., Malone, D. C., & Murphy, J. E. (2012). Recommendations for generating, evaluating, and implementing drug-drug interaction evidence. Pharmacotherapy, 32(4).
  More info

  In October 2009, a 2-day, multistakeholder, national conference was held in Rockville, Maryland, to discuss and propose methods to improve the drug-drug interaction (DDI) evidence base and its evaluation and integration into clinical decision support (CDS) systems. The conference featured participants representing consumers, health care providers, those responsible for relevant policies and guidelines, and developers and vendors of DDI compendia, databases, and CDS systems. One desired outcome of the conference was to prepare recommendations on critical issues surrounding DDI evidence. A set of recommendations was developed to improve the generation, evaluation, and translation of DDI evidence into CDS systems based on presentations by experts and the supporting literature. These recommendations were reviewed initially by conference moderators, speakers, and Scientific Steering and Planning Committee members, and subsequently by all attendees. The following recommendations were developed to increase patient safety by improving the relevance and assessment of DDI evidence: conduct well-designed studies to determine the incidence, outcomes, and patient-level risk factors for DDIs; use a systematic and transparent process for evaluating the DDI evidence in order to estimate the severity and risks of DDIs; and improve the integration of DDI evidence into electronic CDS. Opportunities exist to improve the DDI evidence base, develop and promote a systematic approach for evaluating the evidence, and integrate this evidence into meaningful CDS.
• Murphy, J., Hines, L. E., & Murphy, J. E. (2011). Potentially harmful drug-drug interactions in the elderly: a review. The American journal of geriatric pharmacotherapy, 9(6).
  More info

  Elderly patients are vulnerable to drug interactions because of age-related physiologic changes, an increased risk for disease associated with aging, and the consequent increase in medication use.
• Murphy, J., Warholak, T. L., Holdford, D. A., West, D., DeBake, D. L., Bentley, J. P., Malone, D. C., & Murphy, J. E. (2011). Perspectives on educating pharmacy students about the science of safety. American journal of pharmaceutical education, 75(7).
  More info

  To identify opinions about pharmacy graduates' science of safety (SoS) educational needs.
• Murphy, J., & Murphy, J. E. (2010). The importance of anchors. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 67(19).
• Murphy, J., & Murphy, J. E. (2005). Prediction of gentamicin peak and trough concentrations from six extended-interval dosing protocols for neonates. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 62(8).
  More info

  The ability of six extended-interval gentamicin dosing protocols to achieve desired peak and trough concentrations in neonates was evaluated using simulated calculations based on pooled patient data.
• Murphy, J., & Murphy, J. E. (2004). New Zealand revisited. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 61(11).
• Murphy, J., & Murphy, J. E. (2000). Epistaxis associated with elevation of INR in a patient switched to generic warfarin--a comment. Pharmacotherapy, 20(7).
• Murphy, J., & Murphy, J. E. (2000). Using benchmarking data to evaluate and support pharmacy programs in health systems. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 57 Suppl 2.
  More info

  The use of benchmarking data to evaluate and support pharmacy programs in health systems is discussed. Benchmarking is a method of comparing the outcomes of health care products, services, and practices at an institution against those of competitors in order to learn what might be improved. Benchmarking programs can provide valuable feedback about both positive and negative outcomes. However, it is imperative to avoid inappropriate comparisons and inappropriate assessments. Ideal services for benchmarking are those that have a good likelihood of improving patient care and other outcomes. Successful benchmarking requires sound and thorough data, which is why as many health systems as possible should participate in a benchmarking program. The National Committee for Quality Assurance has formulated guidelines that should enable health systems to develop an information framework that will improve their ability to collect and use data for benchmarking. Standardization in collecting and submitting information is important because it enables institutions to share data easily. Benchmarking can help health-system pharmacists understand the value and outcomes of efforts by their colleagues at other institutions. In addition, benchmarking can help convince health-system administrators of the value of pharmaceutical services in terms of patient care and the bottom line. Benchmarking provides a means of evaluating and supporting the development of pharmacy programs that improve care and save money.
• Murphy, J., & Murphy, J. E. (1999). A call to arms. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 56(7).
• Murphy, J., & Murphy, J. E. (1998). Therapeutic drug monitoring: observations and recommendations. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 55(12).